<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01072435</url>
  </required_header>
  <id_info>
    <org_study_id>a005c</org_study_id>
    <secondary_id>2009-015564-34</secondary_id>
    <nct_id>NCT01072435</nct_id>
  </id_info>
  <brief_title>Target-controlled Infusion Versus Patient-controlled Sedation With Propofol in Endoscopic Retrograde Cholangiopancreatography (ERCP)</brief_title>
  <official_title>Target-controlled Infusion vs Patient-controlled Sedation With Propofol in ERCP. A Randomized Prospective Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Propofol is a drug of choice for deep sedation in endoscopy. Propofol can be administered in
      many ways: by infusion or intravenous boluses and with self-administration device
      (patient-controlled sedation; PCS). It is not clear which method of propofol administration
      would be preferable. The main objective of the trial is to compare 2 different methods of
      propofol administration during ERCP: patient-controlled administration(PCS) and
      target-controlled infusion (TCI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      80 patients of age 18-75 undergoing elective ERCP will be included to the randomized
      non-commercial clinical trial. Exclusion criteria are: allergy to the opioids or propofol,
      dementia, mental retardation, severe liver or kidney insufficiency, significant heart failure
      or lung disease, drug addiction. The endpoints are: ease of procedures performance,
      complications, degree of sedation, recovery time, propofol and opioid consumption. During the
      procedure patients observed and treated by the anaesthesiologist and anaesthesia nurse .
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sedation degrees</measure>
    <time_frame>One day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>patient`s and endoscopist´s satisfaction,</measure>
    <time_frame>One day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>propofol consumption</measure>
    <time_frame>One day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>vital signs:oxygen saturation,blood pressure,heart rate,breathing rate</measure>
    <time_frame>One day</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Sedation</condition>
  <arm_group>
    <arm_group_label>patient-controlled sedation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PCS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>target-controlled infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Patient-controlled sedation</intervention_name>
    <description>Administration of short-acting anesthetic propofol via self-administration device.Single bolus-dose 1ml(10mg)of propofol,lockout time 0sec.,no background infusion or dose-limit.</description>
    <arm_group_label>patient-controlled sedation</arm_group_label>
    <other_name>Arcomed/Syramed AG infusion pump designed for self administration of medicines</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Target-controlled infusion</intervention_name>
    <description>Anaesthesiologist´s managed target-controlled infusion of short-acting anesthetic propofol</description>
    <arm_group_label>target-controlled infusion</arm_group_label>
    <other_name>Arcomed/Syramed AG target-controlled infusion device.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective ERCP patients

        Exclusion Criteria:

          -  allergy to propofol or opioid;

          -  inability to cooperate;

          -  ASA(American Society of Anaesthesiology)class greater than 3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maxim Mazanikov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsiki University Central Hospital,Department of Anaesthesiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marianne Udd, MD.,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital,Department of Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leena Kylänpää, Docent</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital,Department of Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Outi Lindström, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital,Department of Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorma Halttunen, Docent</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital,Department of Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martti Färkilä, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital,Department of Gastroenterology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reino Pöyhiä, Docent</last_name>
    <role>Study Chair</role>
    <affiliation>Helsinki University Central Hospital,Department of Anaesthesiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harri Mustonen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Gastrointestinal and General Surgery, Helsinki University Central Hospital,Helsinki,Finland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsiki University central Hospital,Meilahti Hospital,Endoscopy unit</name>
      <address>
        <city>Helsinki</city>
        <state>Uusimaa</state>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2010</study_first_submitted>
  <study_first_submitted_qc>February 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2010</study_first_posted>
  <last_update_submitted>July 13, 2012</last_update_submitted>
  <last_update_submitted_qc>July 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Maxim Mazanikov</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>ERCP</keyword>
  <keyword>patient-controlled sedation</keyword>
  <keyword>target-controlled infusion</keyword>
  <keyword>propofol</keyword>
  <keyword>Sedation with propofol for ERCP</keyword>
  <keyword>Endoscopic Retrograde Cholangiopancreatography</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

